Clinical trial
Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in…
NCT00192465 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00192465 |
|---|---|
| Title | Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults |
| Official title | A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 (NUMAX TM), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Healthy Adults |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Respiratory Syncytial Virus Infections |
| Intervention type | Biological |
| Interventions | MEDI-524 (Numax-TM) |
| Enrollment | 30 |
| Start date | Nov 1, 2003 |
| Primary completion | Apr 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 29, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: